[PDF][PDF] Clonal heterogeneity and tumor evolution: past, present, and the future
N McGranahan, C Swanton - Cell, 2017 - cell.com
Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …
medicine. Here, we review data and technologies that have revealed intra-tumor …
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Cancer is the leading cause of death worldwide. The complex and disorganized tumor
microenvironment makes it very difficult to treat this disease. The most common in vitro drug …
microenvironment makes it very difficult to treat this disease. The most common in vitro drug …
Molecular landmarks of tumor hypoxia across cancer types
Many primary-tumor subregions have low levels of molecular oxygen, termed hypoxia.
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …
[PDF][PDF] The molecular taxonomy of primary prostate cancer
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …
[PDF][PDF] Integrative clinical genomics of advanced prostate cancer
Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …
Genomic hallmarks of localized, non-indolent prostate cancer
Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …
Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer
Importance The molecular landscape underpinning response to the androgen receptor (AR)
antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer …
antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer …
[PDF][PDF] The evolutionary landscape of localized prostate cancers drives clinical aggression
The majority of newly diagnosed prostate cancers are slow growing, with a long natural life
history. Yet a subset can metastasize with lethal consequences. We reconstructed the …
history. Yet a subset can metastasize with lethal consequences. We reconstructed the …
Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer
AA Hamid, KP Gray, G Shaw, LE MacConaill, C Evan… - European urology, 2019 - Elsevier
Abstract Background TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …
[HTML][HTML] Clinical development of new drug–radiotherapy combinations
RA Sharma, R Plummer, JK Stock… - Nature reviews Clinical …, 2016 - nature.com
In countries with the best cancer outcomes, approximately 60% of patients receive
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …